Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

BMC Neuroscience

Volumn 13, Issue 1, 2012, Pages

  Hunter, Kerry ^a   Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimer disease; Diabetes; Neuroprotection; Parkinson's disease; Stem cells

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; INSULIN; LIRAGLUTIDE; LIXISENATIDE; LYXUMIA; UNCLASSIFIED DRUG; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; ZP10A PEPTIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CELL PROLIFERATION; COGNITION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENTATE GYRUS; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MEMORY; MILD COGNITIVE IMPAIRMENT; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; DOSE RESPONSE; FEMALE; METABOLISM; NERVE CELL;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; MICE; NEUROGENESIS; NEURONS; PEPTIDES;

EID: 84858713174     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-13-33     Document Type: Article

References (23)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157. 10.1053/j.gastro.2007.03.054, 17498508.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548):1696-1705. 10.1016/S0140-6736(06)69705-5, 17098089.
3. Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK. The effect of exenatide re-exposure on safety and efficacy. Peptides 2009, 30(9):1771-1774. 10.1016/j.peptides.2009.06.026, 19576255.
4. Vilsboll T. Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc) 2009, 45(2):101-113.
5. Christensen M, Knop FK, Vilsboll T, Holst JJ. Lixisenatide for type 2 diabetis mellitus. Expert Opin Investig Drugs 2011, 20(4):549-557.
6. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63(7):1187-1192.
7. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004, 82(8):510-529.
8. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 2011, 77(12):1126-1134. 10.1212/WNL.0b013e31822f0435, 21931106.
9. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006, 9(1):13-33.
10. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010, 31(2):224-243. 10.1016/j.neurobiolaging.2008.04.002, 18479783.
11. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010, 5:109-117.
12. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995, 7(11):2294-2300. 10.1111/j.1460-9568.1995.tb00650.x, 8563978.
13. Hamilton A, Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport 2009, 20:1161-1166. 10.1097/WNR.0b013e32832fbf14, 19617854.
14. Gengler S, McClean P, McCurtin R, Gault V, Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2010, DOI:10.1016/j.neurobiolaging.2010.1002.1014.
15. Wang XH, Li L, Holscher C, Pan YF, Chen XR, Qi JS. Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 2010, 170(4):1239-1248. 10.1016/j.neuroscience.2010.08.028, 20727946.
16. McClean P, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011, 31:6587-6594. 10.1523/JNEUROSCI.0529-11.2011, 21525299.
17. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27(3):313-318. 10.1038/sj.ijo.0802206, 12629557.
18. Li Y, Duffy K, Ottinger M, Ray B, Bailey J, Holloway H, Tweedie D, Perry T, Mattson M, Kapogiannis D, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010, 19:1205-1219. 2948479, 20308787.
19. Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011, 60(9):2397-2406. 10.2337/db10-1462, 21810596.
20. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9(9):1173-1179. 10.1038/nm919, 12925848.
21. Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 2011, 89(4):481-489. 10.1002/jnr.22565, 21312223.
22. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002, 45(10):1410-1415.
23. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2005, 2(3):377-385. 10.2174/1567205054367892, 15974903.